Loading
companiesCompany
Flatiron Health (Roche)
Oncology EHR (OncoEMR) and the largest curated real-world oncology database, acquired by Roche for $1.9B in 2018.
Overview
Flatiron Health, based in New York and acquired by Roche for 1.9 billion dollars in 2018, makes the OncoEMR oncology electronic health record and holds the largest curated real-world oncology database. Its data come from about 280 community practices and academic centres, its clinico-genomic database built with Foundation Medicine links treatment records to sequencing, and the data have been used in FDA label expansions and hundreds of publications. OnCo links it to oncology EHR and real-world data platforms and treatment pathway modules, to Roche and Foundation Medicine, and to the term for external and synthetic control arms. Whether real-world data owned by a drug company can serve as a regulatory comparator without conflict is the fair question. The real-world data platform page carries the wider debate.
Headquarters
New York, NY, US
Scorecard
All companies#291of 1244 companies, score 15
- phase 1/2 +3
- modalities +4
- registry trials +8
0 approved, 0 in phase 3, 3 earlier, 0 targets, 15 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Oral CDK inhibitor
Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer.
Phase 2Oral serine/threonine kinase inhibitor
Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.
Phase 2Monoclonal antibody
Selicrelumab is a monoclonal antibody from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.
Similar pages
- CompanyEpic Systems
Shares Oncology EHR modules and treatment pathways, Oncology EHR and real-world data platforms and the tag supporting.
- CompanyTriNetX
Shares Oncology EHR and real-world data platforms, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on and the tag supporting.
- TechnologyFederated learning and privacy-preserving AI
Shares Oncology EHR and real-world data platforms, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow and the tag supporting.
- CompanyOracle Health (Cerner) & Oracle Life Sciences
Shares Oncology EHR modules and treatment pathways and the tag supporting.
- TechnologyOncology pharmacy automation and compounding robots
Shares Oncology EHR modules and treatment pathways and the tag supporting.
- TechnologyWhole-slide scanners and image management
Shares AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, Roche / Genentech and the tag supporting.
- CompanyConcertAI
Shares Oncology EHR and real-world data platforms and the tag supporting.
- CompanyCOTA
Shares Oncology EHR and real-world data platforms and the tag supporting.
fronts
technologies
drugs
Phase 2Oral serine/threonine kinase inhibitor
Phase 2Oral CDK inhibitor
Phase 2Monoclonal antibody
companies
terms
trials
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate CancerA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACA Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment PeriodA Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell LymphomaA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± ObinutuzumabStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
roadmaps
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A de-identified oncology database assembled from the electronic records of the practices Flatiron sells software to, used for external control arms and regulatory submissions.
Flatiron Health (Roche)Paper 2020An oncology-specific electronic record used by community practices in the United States, and the point of care that feeds Flatiron's real-world database.
Flatiron Health (Roche)Paper 2014